Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
Cécile Denis, director of research at INSERM, shared a post on LinkedIn:
”The result of an almost 10-year journey: a bispecific nanobody bridging von Willebrand factor to albumin in order to prolong the half-life of VWF and increasing its plasma levels. A potential treatment for patients with decreased VWF levels (Type 1 VWD).
We should not forget that Von Willebrand disease remains largely underestimated and therefore untreated, especially in type 1 patients.
Thank you Ivan Peyron, Caterina Casari, Geneviève McCluskey, Stéphanie Roullet, Vincent Licari, Emilie BOCQUET, Claire Auditeau, Melanie Daniel, sophie susen, Olivier Christophe, Peter Lenting, HITh lab Inserm, INSERM, ANR Agence nationale de la recherche.”
Read the full study here.
Title: A bispecific nanobody for the treatment of von Willebrand disease type 1
Authors: Ivan Peyron, Caterina Casari, Genevieve McCluskey, Stéphanie Roullet, Vincent N Licari, Emilie Bocquet, Claire Auditeau, Melanie Y Daniel, Sophie Susen, Olivier D. Christophe, Peter J Lenting, Cécile V. Denis
Stay updated with Hemostasis Today.
-
Jul 27, 2026, 16:57Thomas Dayspring։ Could PCSK9 Inhibitors Reduce the Risk of Retinal Vascular Occlusions?
-
Jul 27, 2026, 16:53Arun V. J.: How to Find a Mentor When You Know No One
-
Jul 27, 2026, 16:45Urtė Cholinaitė: A Meaningful Experience at the Lithuania Hemophilia Society Summer Camp
-
Jul 27, 2026, 16:33Martyna Lewand: Major Immunology Deal Brings FB102 to argenx
-
Jul 27, 2026, 16:30Jean Amiral: Laboratory differentiation of HIT, VITT and PF4 dependent Thrombocytopenias
-
Jul 27, 2026, 15:40Afila Thasnim: Blood Crossmatching Challenges and Safe Transfusion Decisions
-
Jul 27, 2026, 14:30William McKeown Elected Vice-President of the EHC
-
Jul 27, 2026, 13:54Nahid A. Qushmaq: Advancing Anticoagulation Through Factor XI/XIa Inhibition
-
Jul 27, 2026, 13:45The Essentials of FFP Dosing and Monitoring – ICHCC